Sign in Subscribe
Stock offerings

Incannex Healthcare Announces Limited Utilization of At-the-Market Offering Program

Strategic Insights

— 2 min read

Incannex Healthcare Inc., a leading developer of combination medicines for chronic conditions, announced that it does not intend to utilize the full capacity available under its at-the-market offering program (ATM) in the near-term. The Company had utilized the ATM on July 30, 2025, selling approximately 9.2 million shares of its common stock, which represented only 1.97% of the reported daily trading volume for the day. Prior to yesterday's activity, the Company had not utilized the ATM facility since July 17. With a strong current cash balance of approximately US$50 million, Incannex is well-positioned to advance its portfolio of drug candidates through the next stages of development. CEO Joel Latham emphasized the Company's commitment to balancing the need to fund its clinical and commercial objectives with the importance of minimizing dilution for shareholders.

Key Takeaways:

  • Incannex Healthcare Inc. announced that it does not intend to use the full capacity available under its at-the-market offering program (ATM) in the near-term.
  • The Company utilized the ATM on July 30, 2025, selling approximately 9.2 million shares of its common stock, which represented only 1.97% of the reported daily trading volume for the day.
  • Prior to yesterday's activity, the Company had not utilized the ATM facility since July 17.
  • Incannex has a strong current cash balance of approximately US$50 million, enabling it to advance its portfolio of drug candidates through the next stages of development.
  • The Company's lead clinical program, IHL-42X, has shown statistically significant improvements across key clinical endpoints and a superior safety profile.
  • Incannex is advancing three clinical-stage product candidates based on evidence-based innovation and supported by streamlined operations.
  • The Company is committed to minimizing dilution for shareholders while balancing the need to fund its clinical and commercial objectives.
  • Incannex's pipeline includes IHL-675A, an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate for the treatment of inflammatory conditions, and PSX-001, an oral synthetic psilocybin treatment for generalized anxiety disorder.

Statistics:

  • 9.2 million shares of Incannex's common stock were sold through the ATM on July 30, 2025, representing 1.97% of the daily trading volume.
  • Incannex had a cash balance of approximately US$50 million as of the announcement date.
  • The Company's lead clinical program, IHL-42X, has shown statistically significant improvements across key clinical endpoints, including a superior safety profile.
  • Incannex is advancing three clinical-stage product candidates, including IHL-675A and PSX-001.

Sources:

  • Incannex Healthcare Inc. press release, July 31, 2025
  • U.S. Securities and Exchange Commission (SEC) filings, including the Company's annual report on Form 10-K for the fiscal year ended June 30, 2024, filed with the SEC on September 30, 2024.

Read more